halobetasol propionate (BioDeep_00000614968)

   


代谢物信息卡片


(1R,8S,13S,14R)-14-(2-chloroacetyl)-1,8-difluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl propanoate

化学式: C25H31ClF2O5 (484.1828)
中文名称: 卤倍他索丙酸酯
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CCC(=O)OC1(C(CC2C1(CC(C3(C2CC(C4=CC(=O)C=CC43C)F)F)O)C)C)C(=O)CCl
InChI: InChI=1S/C25H31ClF2O5/c1-5-21(32)33-25(20(31)12-26)13(2)8-15-16-10-18(27)17-9-14(29)6-7-22(17,3)24(16,28)19(30)11-23(15,25)4/h6-7,9,13,15-16,18-19,30H,5,8,10-12H2,1-4H3/t13-,15-,16-,18-,19-,22-,23-,24-,25-/m0/s1

描述信息

C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C1636 - Therapeutic Steroid Hormone
C308 - Immunotherapeutic Agent > C574 - Immunosuppressant > C211 - Therapeutic Corticosteroid
D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents

同义名列表

2 个代谢物同义名

halobetasol propionate; (1R,8S,13S,14R)-14-(2-chloroacetyl)-1,8-difluoro-17-hydroxy-2,13,15-trimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl propanoate



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Paulina Carvajal-Vidal, Roberto González-Pizarro, Carolina Araya, Marta Espina, Lyda Halbaut, Immaculada Gómez de Aranda, M Luisa García, Ana C Calpena. Nanostructured lipid carriers loaded with Halobetasol propionate for topical treatment of inflammation: Development, characterization, biopharmaceutical behavior and therapeutic efficacy of gel dosage forms. International journal of pharmaceutics. 2020 Jul; 585(?):119480. doi: 10.1016/j.ijpharm.2020.119480. [PMID: 32479897]
  • Paulina Carvajal-Vidal, María-José Fábrega, Marta Espina, Ana Cristina Calpena, M Luisa García. Development of Halobetasol-loaded nanostructured lipid carrier for dermal administration: Optimization, physicochemical and biopharmaceutical behavior, and therapeutic efficacy. Nanomedicine : nanotechnology, biology, and medicine. 2019 08; 20(?):102026. doi: 10.1016/j.nano.2019.102026. [PMID: 31170512]
  • Mahesh L Bikkad, Ajaz H Nathani, Satish K Mandlik, Shilpa N Shrotriya, Nisharani S Ranpise. Halobetasol propionate-loaded solid lipid nanoparticles (SLN) for skin targeting by topical delivery. Journal of liposome research. 2014 Jun; 24(2):113-23. doi: 10.3109/08982104.2013.843192. [PMID: 24131382]
  • H S Zackheim, M Kashani-Sabet, S Amin. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Archives of dermatology. 1998 Aug; 134(8):949-54. doi: 10.1001/archderm.134.8.949. [PMID: 9722724]
  • P Walsh, J L Aeling, L Huff, W L Weston. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. Journal of the American Academy of Dermatology. 1993 Sep; 29(3):501-3. doi: 10.1016/s0190-9622(08)82011-7. [PMID: 8349876]
  • S Yawalkar, I Wiesenberg-Boettcher, J R Gibson, S B Siskin, W Pignat. Dermatopharmacologic investigations of halobetasol propionate in comparison with clobetasol 17-propionate. Journal of the American Academy of Dermatology. 1991 Dec; 25(6 Pt 2):1137-44. doi: 10.1016/0190-9622(91)70312-p. [PMID: 1757603]
  • W A Watson, R E Kalb, S B Siskin, J P Freer, L Krochmal. The safety of halobetasol 0.05\% ointment in the treatment of psoriasis. Pharmacotherapy. 1990; 10(2):107-11. doi: NULL. [PMID: 2349135]